Genpharmasec Limited

ADIRASA

INE861N01036

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 02:33:06 05/07/2024 pm IST			5-day change	1st Jan Change
2.39 ^INR	-2.05%		+16.50%	-48.61%

24/05	Genpharmasec Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
24/05	Genpharmasec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Adi Rasayan Limited has Changed its Name to Generic Pharmasec Limited

November 27, 2018 at 10:30 am IST

On November 27, 2018, Adi Rasayan Limited changed its name to Generic Pharmasec Limited.

Latest news about Genpharmasec Limited

Genpharmasec Limited Reports Earnings Results for the Full Year Ended March 31, 2024	24/05	CI
Genpharmasec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	24/05	CI
Genpharmasec Limited Announces Appointment of Hardik Makwana as Company Secretary & Compliance Officer	27/03	CI
Genpharmasec Limited Announces Resignation of Heta Shah as Company Secretary / Compliance Officer	20/03	CI
Genpharmasec Limited Announces Resignation of Ulhas Narayan Deosthale from the Post of Executive Director	12/03	CI
Genpharmasec Limited completed the acquisition of an unknown stake in Derren Healthcare Private Limited from the existing shareholder.	11/03	CI
Genpharmasec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Genpharmasec Forms Subsidiary for Molecular Testing Services	29/01	MT
Genpharmasec Limited Forms New Wholly Owned Subsidiary Company Namely Clinigenome India Private Limited	29/01	CI
Genpharmasec Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Genpharmasec to Acquire 70% Stake in Derren Healthcare for INR126.4 Million	20/23/20	MT
Genpharmasec Limited signed a share purchase agreement to acquire an unknown stake in Derren Healthcare Private Limited from the existing shareholder for approximately INR 130 million.	19/23/19	CI
Genpharmasec Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Genpharmasec Sets Up Middle East Unit	14/23/14	MT
Genpharmasec Limited Incorporates Foreign Subsidiary Namely Genpharmasec Middle East DMCC	14/23/14	CI
Genpharmasec Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	26/23/26	CI
Genpharmasec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Genpharmasec Limited Announces Board Changes	01/22/01	CI
Genpharmasec Limited Announces CFO Changes	01/22/01	CI
Genpharmasec Limited Appoints Heta Shah as Company Secretary and Compliance Officer, with Effect from October 7, 2022	07/22/07	CI
Genpharmasec Limited Announces Resignation of Amisha Mitesh Dani as Independent Director	06/22/06	CI
Genpharmasec Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/22/10	CI
Genpharmasec Limited Announces Executive Appointments	04/22/04	CI
Genpharmasec Limited Announces Director Resignations with Effect from June 21, 2022	21/22/21	CI
Genpharmasec Limited Announces Resignation of Independent Directors	18/22/18	CI

Genpharmasec Ltd is an India-based company, which is engaged in the distribution of the lucrative medical and diagnostics device segment. It is engaged in providing technology-based medical and diagnostics devices. The Company operates through two segments: Distribution of Diagnostic Equipmentâs and Investment and trading in Securities. The Company holds rights for distribution of equipments, such as i-STAT Analyzers and its Cartridges manufactured by Abbott Point of Care, USA all over India. The Company also holds distribution rights of Sphingotec Biomarkers and Joinstar System through Rivaara Labs Private Limited.

Sector

Pharmaceuticals

Calendar

23/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENPHARMASEC LIMITED	-48.61%	16.18M
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.54%	624B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.75%	240B
ROCHE HOLDING AG	+0.45%	219B
NOVARTIS AG	+14.60%	220B
AMGEN INC.	+7.42%	166B